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Dear Editor,
A 22-year-old woman presented with generalized petechiae
for 1 week, and complete blood count revealed an isolated
thrombocytopenia of 6×10
9/L. Blood film examination was
normal except thrombocytopenia. Physical examination
showed no palpable lymphadenopathy or hepatosplenome-
galy. Bone marrow biopsy showed megakaryocytic hyper-
plasia only, and a diagnosis of acute primary immune
thrombocytopenia (ITP) was made. Intravenous immune
globulin (IVIg; 0.5 gkg
−1day
−1 for 4 days) was started with
no increase in platelet count. Oral prednisolone at 50 mg
daily (1 mg/kg) was added subsequently, but the platelet
count remained below 10×10
9/L for another 2 weeks.
Although she had no clinical symptoms and signs of
thyrotoxicosis, thyroid function test was requested in view
of the presence of a small goiter. The blood test revealed a
raised free T4 with suppressed TSH level, and the anti-
thyrogobulin and anti-microsomal antibodies were also
increased, compatible with a diagnosis of Graves’ disease.
Carbimazole was therefore initiated while prednisolone was
continued concurrently for the ITP. Intriguingly, the platelet
count showed a progressive improvement with a parallel
reduction of the free T4. At 3 and 5 weeks after starting the
carbimazole, the platelet counts were 83 and 182×10
9/L
when the dose of prednisolone was also reduced to 30 and
15 mg, respectively.
The association between hyperthyroidism and thrombo-
cytopenia was first described in 1931 [1]. Autoimmune
thyroid disorders including Graves’ disease and Hashimo-
to’s thyroiditis have subsequently been reported in patients
with ITP. In a recent standardization of terminology, ITP
with concurrent autoimmune disease has been designated as
secondary ITP which may require a different approach to
management [2]. This distinction, however, is not well
defined in cases of ITP associated with autoimmune thyroid
diseases. Simultaneous presentation of ITP and autoim-
mune thyroid disease is often seen, but the timing between
the two diagnoses can vary from months to years [3].
Several mechanisms connecting thyroid disorders and
thrombocytopenia have been described. Mild thrombocyto-
penia is frequently observed in patients with Graves’
disease [4]. Platelet life span has been shown to be
significantly shortened in patients with hyperthyroidism
[5]. Increased reticuloendothelial phagocytic activity by
upregulation of Fc receptor expression or activity is a
potential mechanism [6]. Significant immune dysregulation
in patients with thyroid dysfunction and ITP is evidenced
by the increased prevalence of antiplatelet and antithyroid
antibodies in these patients [7]. Platelet-associated IgG or
specific platelet antibodies occurred in 83% and 86% of
patients with ITP with and without autoimmune thyroid
disease, respectively [7]. Thyroid autoantibodies, on the
other hand, were detected in 89% of patients with ITP and
autoimmune thyroid disease [7]. Genetic predisposition to
the concurrence of ITP and hyperthyroidism has also been
suggested. HLA B8 is the commonest antigen reported in
patients with isolated ITP and Graves’ disease [8–10].
Given the well-established association between the two
conditions, treatment of the coexisting thyroid disorder has
been reported to induce remission of ITP or result in an
improved response to standard ITP therapy [3]. As
illustrated in our case, treatment of the Graves’ disease
did result in a significant improvement of thrombocytope-
nia that had been refractory to IVIg and steroid treatment.
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